FEATURED ARTICLES
-
![Tobias_Struller_2025]( "Tobias Struller, Manager, Process Performance & Qualification")
Tobias Struller, Manager, Process Performance & QualificationTobias provides insight into the challenges of manufacturing cytotoxic and noncytotoxic drugs together in a multiproduct facility.
WHITE PAPERS & CASE STUDIES
-
![GettyImages-1298781737 aseptic filling]( "Vaccine Fill Line Operations")
Vaccine Fill Line OperationsLearn how adopting a harmonized, risk-based validation strategy across global sites can reduce operational readiness timelines and drive improvements in equipment effectiveness and regulatory compliance
-
![GettyImages-2173467618-vials-conveyor-belt]( "GMP Manufacturing Cycle Time Reduction")
GMP Manufacturing Cycle Time ReductionIdentifying process redundancies and enhancing visual management allows manufacturers to stabilize workflows. These data-driven improvements can decrease operational variability by nearly 50%.
-
![GettyImages-109727565 mold]( "Mold In Cleanrooms: A Persistent Threat And The Case For Proactive Bio-Decontamination")
Mold In Cleanrooms: A Persistent Threat And The Case For Proactive Bio-DecontaminationLearn how a comprehensive investigation and systems-level bio-decontamination strategy successfully eliminated persistent mold contamination in a vaccine manufacturing facility's high-risk area.
-
![GettyImages-1218745370 cleanroom, disinfecting, lab]( "Contamination In The Shadows: Risks Lurking From Environmental Issues")
Contamination In The Shadows: Risks Lurking From Environmental IssuesDiscover how science-based bio-decontamination strategies effectively eliminate invisible pathogens and rapidly restore facilities to operational safety following major infrastructure disruptions.
-
![GettyImages-2151295139-computer-hands-technology]( "Ringing The Alarm: Unified Data For GMP Annex 1 Compliance")
Ringing The Alarm: Unified Data For GMP Annex 1 ComplianceAlarm monitoring can be more than compliance. Learn how unified data and real-time insights helped one pharma company unlock efficiency, predictive analytics, and a path to digital transformation.
-
![Epigenetic therapies of the future_GettyImages-2203738408]( "Build An AAV8 Platform: Lessons From A Collaborative Development Journey")
Build An AAV8 Platform: Lessons From A Collaborative Development JourneyExplore how a modular AAV8 platform enables scalable, GMP-ready gene therapy manufacturing with reproducible outcomes, streamlined tech transfer, and adaptability across serotypes.
PRODUCTS & SERVICES
Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.
Accelerate your gene therapy manufacturing with the Xcellerex™ X-platform – a next-generation single-use bioreactor system designed for viral vector workflows.
Whether you're looking to boost performance, enhance your capabilities, or simply get consistent, high-quality results, HyClone™ peak expression medium and HyClone™ prime expression medium are the solutions for you.
ÄKTA ready™ 450 system is a single-use liquid chromatography system.
The LevMixer™ 10 L single-use mixing system is a low volume mixer designed for both upstream and downstream applications.
Track and manage defects and non-conformances – such as SOP deviations or missing data – from identification to resolution.
Enforce standardized workflows while collecting data in real time, giving you the visibility you need to prevent deviations, review exceptions, and release batches faster.
The journey of a GLP-1 receptor agonist (GLP-1 RA) molecule is complex.